

**FORM 51-102F3  
MATERIAL CHANGE REPORT**

**Item 1            Name and Address of Company**

BioVaxys Technology Corp. (the “Company”)  
146 Thirtieth Street, Suite 100  
Etobicoke, Ontario  
Canada M8W 3D4

**Item 2            Date of Material Change**

April 30, 2024

**Item 3            News Release**

The Company disseminated a news release announcing the material change described herein through the news dissemination services of PR Newswire on April 30, 2024, and a copy was subsequently filed on SEDAR+.

**Item 4            Summary of Material Change**

The Company announced that it has appointed Christopher Cherry as Chief Financial Officer.

**Item 5            Full Description of Material Change**

**5.1                Full Description of Material Change**

The Company announced that it has appointed Christopher Cherry as Chief Financial Officer. Mr. Cherry, a Chartered Accountant and Certified Public Accountant, has extensive experience, having served as a CFO of many public issuers in a broad range of sectors.

Mr. Cherry’s responsibilities will include full cycle accounting, supervision and planning, financial statement preparation, management discussion and analysis preparation, budgeting, cash flow activities, financing, auditor communication, and taxes. Aside from his vast experience as CFO and/or Director of a number of public issuers, Mr. Cherry has previously worked as a Senior Auditor with Davidson & Company LLP and a Senior Accountant with KPMG LLP.

**5.2                Disclosure for Restructuring Transactions**

Not applicable.

**Item 6            Reliance on Subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7            Omitted Information**

Not applicable.

**Item 8            Executive Officer**

For further information, please contact James Passin, Chief Executive Officer of the Company, at +1 646 452 7054.

**Item 9            Date of Report**

May 7, 2024